Tuberculosis protein linked to diabetes-like changes

Diabetes is well known to increase the risk of tuberculosis (TB), but growing clinical evidence also suggests the reverse: TB can trigger high blood sugar (hyperglycaemia) and insulin resistance. Until now, the specific components of Mycobacterium tuberculosis (Mtb) that might drive those metabolic changes were unclear. In new work led by corresponding author Sangita Mukhopadhyay, researchers focused on a secreted protein called PPE2, which belongs to the PE/PPE family of Mtb proteins. The team studied how PPE2 affects fat tissue and whole-body metabolism using animal models and molecular analyses. Their aim was to see whether a single mycobacterial factor could alter adipose tissue physiology and thereby contribute to the glucose and insulin disturbances observed during TB. The study traced changes from tissue structure to gene expression and circulating metabolites, comparing effects seen in mice with markers detected in human TB patient sera. By isolating the action of PPE2, the researchers sought to bridge clinical observations of TB-associated metabolic problems with a concrete microbial cause, opening the door to targeted interventions against this specific protein.

The investigators report that PPE2 produced marked changes in fat tissue and metabolism in mice. PPE2 exposure caused fat loss alongside adipocyte hypertrophy and immune cell infiltration in adipose tissue, and mice showed impaired glucose tolerance and higher insulin resistance. At the molecular level, PPE2 reduced expression of key adipose genes PPAR-γ, C/EBP-α and adiponectin. Transcriptomic analysis revealed that PPE2 altered expression of genes associated with chemokine/cytokine signaling, ribosomal biogenesis and lipase signaling. Functionally, PPE2 induced lipolysis by activating the cAMP–PKA–HSL axis, which led to increased circulating free fatty acids — a change the authors also observed in TB patient sera. Importantly, PPE2-immunization mitigated these effects in the experimental system, suggesting that immune targeting of this single protein can blunt the metabolic disturbances it causes. Throughout, the work centers PPE2, a secretory PE/PPE family protein of Mycobacterium tuberculosis (Mtb), as the microbial driver of the observed adipose and metabolic changes.

These findings link a defined mycobacterial protein to the metabolic symptoms seen in TB, positioning PPE2 as a key bridge between Mtb infection, adipose tissue dysfunction and insulin resistance. If PPE2 produces the same effects in humans as in the mouse studies, it could help explain why TB sometimes precipitates hyperglycaemia and worsen diabetes-related outcomes. The observation that PPE2-immunization lessened the harmful effects raises the possibility of a subunit vaccine strategy aimed not only at preventing infection but also at preventing TB-driven metabolic complications. The identification of increased circulating free fatty acids in both the mouse model and TB patient sera suggests a measurable biomarker that might be used to monitor or diagnose TB-associated metabolic disturbance. Overall, the work reframes how clinicians and researchers might think about the interactions between infectious disease and metabolic health, and it points to PPE2 as a specific target for further study and potential intervention.